<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-05-06" updated="2020-01-02">
  <drugbank-id primary="true">DB09051</drugbank-id>
  <name>Elosulfase alfa</name>
  <description>Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.</description>
  <cas-number>9025-60-9</cas-number>
  <unii>ODJ69JZG85</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7658</ref-id>
        <pubmed-id>24700469</pubmed-id>
        <citation>Sanford M, Lo JH: Elosulfase alfa: first global approval. Drugs. 2014 Apr;74(6):713-8. doi: 10.1007/s40265-014-0210-z.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). </indication>
  <pharmacodynamics>AUC: 238 min x μg/mL, standard deviation 100. </pharmacodynamics>
  <mechanism-of-action>Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity. The sulfatase activity deficiency results in the accumulation of the GAG substrates, KS and C6S, in the lysosomal compartment of cells throughout the body. The accumulation leads to widespread cellular, tissue, and organ dysfunction. Vimizim is intended to provide the exogenous enzyme N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S. Elosulfase alfa uptake by cells into lysosomes is mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of elosulfase alfa to mannose-6-phosphate receptors.&#13;
&#13;
In the absence of an animal disease model that recapitulates the human disease phenotype, elosulfase alfa pharmacological activity was evaluated using human primary chondrocytes from two MPS IVA patients. Treatment of MPS IVA chondrocytes with elosulfase alfa induced clearance of KS lysosomal storage from the chondrocytes.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Cmax: 1.49 μg/mL, standard deviation 0.534.</absorption>
  <half-life>week 0: 7.52 min&#13;
week 22: 35.9 min</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution>396 mL/kg, standard deviation 316.</volume-of-distribution>
  <clearance>10.0 mL/min/kg. &#13;
(standard deviation: 3.73). </clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">N-acetylgalactosamine-6-sulfatase</synonym>
  </synonyms>
  <products>
    <product>
      <name>Vimizim</name>
      <labeller>Biomarin International Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02427184</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Vimizim</name>
      <labeller>BioMarin Pharmaceutical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68135-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution, concentrate</dosage-form>
      <strength>5 mg/5mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA125460</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Vimizim</name>
      <ingredients>Elosulfase alfa</ingredients>
    </mixture>
    <mixture>
      <name>Vimizim</name>
      <ingredients>Elosulfase alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbon-Oxygen Lyases</category>
      <mesh-id>D019757</mesh-id>
    </category>
    <category>
      <category>Chondroitinases and Chondroitin Lyases</category>
      <mesh-id>D002810</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Esterases</category>
      <mesh-id>D004950</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lyases</category>
      <mesh-id>D008190</mesh-id>
    </category>
    <category>
      <category>Polysaccharide-Lyases</category>
      <mesh-id>D011133</mesh-id>
    </category>
    <category>
      <category>Recombinant Proteins</category>
      <mesh-id>D011994</mesh-id>
    </category>
    <category>
      <category>Sulfatases</category>
      <mesh-id>D013429</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution, concentrate</form>
      <route>Intravenous</route>
      <strength>5 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>1 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AB12">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>44:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09051.pdf?1430948733</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences>
    <sequence format="FASTA">&gt;Elosulfase-alfa
APQPPNILLLLMDDMGWGDLGVYGEPSRETPLCSPSRAALLTGRLPIRNGFYTTNAHARN
LLKKAGYVSKIVGKWHLGHRPQFHPLKHGFNIPVYRDWEMVGRYYEEFPINLKTGEANLT
FLYWAVDATHAPVYASKPFLGTSQRGRYGDVADNTFVFFTSDNGAALISAPEQGGSNGPF
PGHVTAGQVSHQLGSIMDLFTTSLALAGLTLMDRPIFYYRGDTLMAATLGQHKAHFWTWT
VTTHNLEDHTKLPLIFHLGRDPGERFPLSFEALVPAQPQLNVCNWAVMNWAPPGCEKLGK
PNLDRMAAEGLLFPNFYSANAYTPQEIVGGIPDSEQLLPEDEWFGSPNCHFGPYDNKARP
QIYLQEALDFIKRQARHHPFAVREIDDSIGKILELLQDLHLCGKQTTFEGGMREPALAWW
PPSDRAIDGLNLLPTLLQGRNSWENFRQGIDFCPGQNVSGASAEYQEALSRITSVVQQHQ
CLTPPESIPKKCLWSH</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>110800.0</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C5020H7588N1364O1418S34</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22450</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910399</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10333</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P34059</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Elosulfase_alfa</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2108676</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/elosulfase-alfa.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>